东非和南部非洲HIV疫苗试验中参与者对试验设计的理解与参与可接受性:一项纵向定性研究
本研究在PrEPVacc试验(IIb期三臂两阶段HIV预防性疫苗试验,含口服暴露前预防二次随机)中开展纵向定性研究,于2021年10月至2023年9月对105名参与者进行三次深度访谈,并组织111人参与14场焦点小组讨论。结果显示,经卫生工作者反复信息共享,参与者对随机化、双盲和安慰剂对照理解良好;污名与错误信息构成参与障碍。
要点
- 卫生工作者反复沟通可提升参与者对随机化、双盲和安慰剂对照的理解。
- PrEP被广泛视为实验性疫苗之外的保护措施,个体感知HIV风险是坚持PrEP的主要动机。
- 社区污名与错误信息构成参与障碍,部分参与者遭受社会伤害。
核心结论
- 参与者对随机化、双盲和安慰剂对照展现良好理解,得益于卫生工作者清晰反复的沟通。
研究设计与样本
- 纵向定性研究嵌套于PrEPVacc试验(IIb期、三臂、两阶段HIV预防性疫苗试验,含口服PrEP二次随机)。
- 105名参与者(占试验参与者7%)被 purposively 选取,在2、6、12个月接受三次深度访谈。
- 另111人(92名女性、19名男性)在四个站点参与14场焦点小组讨论。
- 数据收集时间为2021年10月至2023年9月,采用主题分析法。
主要发现
- 卫生工作者引导的反复信息共享会帮助参与者理解关键试验概念和设计。
- PrEP被广泛认可为与实验性疫苗并列的保护措施。
- 疫苗因便利和副作用少而受偏好,个体感知HIV风险是坚持PrEP的主要动机。
- 与卫生工作者及密切家庭成员的支持性关系鼓励参与试验,包括接受使用产品。
- 社区中的错误信息和污名构成参与障碍,部分参与者面临社会伤害。
关键数值与推荐
- 试验注册号:ClinicalTrials.gov NCT04066881,注册日期2020年12月15日。
临床怎么用
- 需强化策略以提升知情同意、减少污名并促进试验接受度,从而保障试验成功实施与保留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This qualitative study was conducted to assess participants' understanding of the PrEPVacc trial design and factors that influenced decisions to participate in the trial. PrEPVacc was a phase IIb, three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to oral pre-exposure prophylaxis. The main objective was to assess the safety and efficacy of two HIV-1 prophylactic vaccine regimens, each compared to placebo, in preventing the acquisition of HIV. METHODS: Using a longitudinal approach, qualitative data were collected between October 2021 and September 2023. A sample of 105 participants (7% of trial participants) was purposively selected to participate in three in-depth interviews at 2, 6, and 12 months during the trial. Another 111 (92 females and 19 males) participated in 14 focus group discussions across four sites. Data were analyzed thematically. RESULTS: Repeated information sharing sessions facilitated by health workers helped participants understand key trial concepts and the design. Pre-exposure prophylaxis (PrEP) was widely recognised as a protective measure alongside experimental vaccines. While vaccines were preferred for convenience and minimal side effects, individual perceived HIV risk was a main motivation for adhering to PrEP. Supportive relationships with health workers and close family members encouraged engagement in the trial, including acceptance to use the products. However, misinformation and stigma in communities created barriers to participation, with some participants facing social harm. CONCLUSION: Overall, participants demonstrated a good understanding of randomisation, double-blinding, and placebo control, facilitated by clear, repeated communication from health workers. Strengthening strategies to enhance informed consent, reduce stigma, and promote trial acceptance is crucial for successful implementation and retention. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT04066881. Registered on December 15, 2020.
引用
- Kawuma R, Nakamanya S, Tarimo E, et al. Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study. Trials. 2026. PMID: 42141483. doi:10.1186/s13063-026-09774-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。